Attached files
| file | filename |
|---|---|
| EX-99.3 - PRESS RELEASE - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | celz_ex993.htm |
| EX-99.2 - PRESS RELEASE - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | celz_ex992.htm |
| EX-99.1 - PRESS RELEASE - CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | celz_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 22, 2020
| Creative Medical Technology Holdings, Inc. |
| (Exact name of registrant as specified in its charter) |
| Nevada |
| 000-53500 |
| 87-0622284 |
| (State or other jurisdiction |
| (Commission File Number) |
| (I.R.S. Employer |
| of incorporation) |
|
|
| Identification Number) |
| 211 E Osborn Road, Phoenix, AZ 85012 |
| (Address of principal executive offices) |
(833) 336-7636
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| N/A | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01. Other Events
On December 22, 2020, Creative Medical Technologies, Inc. (the “Company”), issued a press release identifying one of the primary mechanisms of action of its ImmCelz® product in the treatment of stroke.
On December 29, 2020, the Company issued a press release reporting on data and a related patent filing with respect to the ability of ImmCelz® to reverse liver failure in the carbon tetrachloride preclinical model of hepatocyte necrosis.
On December 31, 2020, the Company issued a press release reporting on a patent filing based on positive preclinical data using ImmCelz® in the treatment of a model of heart attack.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Press Releases issued by the Company dated December 22, 2020 | |
|
|
|
| Press Releases issued by the Company dated December 29, 2020 | |
|
|
|
| Press Releases issued by the Company dated December 31, 2020 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| Creative Medical Technology Holdings, Inc. |
| |
|
|
|
| |
| Date: January 4, 2021 | By: | /s/ Timothy Warbington |
|
|
|
| Timothy Warbington, Chief Executive Officer |
|
| 3 |